SinoMab Bioscience, a Hong Kong Biotech, to IPO on Hong Kong Exchange
publication date: Jul 10, 2019
SinoMab Bioscience, a Hong Kong clinical-stage antibody company, reported its filing for a Hong Kong IPO has been accepted by the Exchange. Founded in 2001 by Dr. Shawn Leung, the company has two mAbs in clinical development against targets for autoimmune diseases (rheumatoid arthritis, systemic lupus erythematosus,) and cancer (non-Hodgkin’s lymphoma). It has another four mAbs in pre-clinical development. SinoMab claims particular expertise in hybridization technology for mAbs. Headquartered in Hong Kong, SinoMab has additional facilities in Shenzhen, Hainan and Suzhou. More details....
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.